Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices

American Journal of Managed Care

Volumn 8, Issue 11, 2002, Pages 937-946

  Walsh, Mary N ^a   Simpson Jr , Ross J ^b   Wan, George J ^c   Weiss, Thomas W ^d   Alexander, Charles M ^d   Markson, Leona E ^d   Berger, Marc L ^d   Pearson, Thomas A ^e  

^a Care Group   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PFIZER INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EXERCISE; FEMALE; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HUMAN; HYPERTENSION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING CESSATION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DISEASE MANAGEMENT; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT EDUCATION; PROGRAM EVALUATION; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 0036859856     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study. Lancet. 1995;345:1274-1275.
2. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;33:1349-1357.
5. Downs JR, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
7. GISSI Investigators. Six month effects of lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: The GISSI-3 Trial. J Am Coll Cardiol. 1996;27:337-344.
8. HOPE Study Investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
9. Pfeffer MA, Brunwald E, Move LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
11. Hansson L, Zanchetti A, Carruthers SF, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
12. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens. 2000;13(4):418-426.
13. Pedersen TR. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
14. Johannesson M, Johnsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336.
15. Caro J, Klittich W, McGuire A, et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. Eur Heart J. 1999;20:263-268.
16. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol. 1998;82:1357-1363.
17. Glick H, Cook J, Bourassa M, et al. Projections of the costs and benefits of enalapril treatment in patients with symptomatic heart failure [abstract]. J Am Coll Cardiol. 1994;23:284A.
18. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Cost and effectiveness of routine therapy with beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988;319:152-157.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
20. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Presure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program. Bethesda, MD: National Heart, Lung, and Blood Institute; November 1997. NIH publication 98-4080.
21. Smith SC, Blair SN, Criqui MH, et al, and the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
22. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation. 2001;104:1577-1579.
23. Pearson TA, Peters TD, Feury D, for the ACCEPT Study. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study: Attainment of goals for comprehensive risk reduction in patients with coronary disease in the US [abstract]. J Am Coll Cardiol. February 1998:186A.
24. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol. 1997;29:139-146.
25. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med. 2000;160:459-467.
26. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-717.
27. Massing MW, Sueta CA, Chowdhury M, Biggs BP, Simpson RJ. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 2001;87:646-649.
28. Sueta CA, Chowdhury M, Boccuzzi S, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
29. Simpson RJ, Weiser RR, Naylor S, Sueta CA, Metts AK. Improving care for unstable angina patients in a multiple hospital project sponsored by a federally designated quality improvement organization. Am J Cardiol. 1997;80(8B):80H-84H.
30. Fonarow GC, French WJ, Parsons LS, Haili S, Malmgren JA, for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. Circulation. 2001;103:38-44.
31. Smith S. Need for a paradigm shift: The importance of risk factor reduction therapy in treating patients with cardiovascular disease. Am J Cardiol. 1998;82(10B):10T-13T.
32. Shepherd J, Alcalde V, Befort P, et al. International comparison of awareness and attitudes towards coronary risk factor reduction: The HELP study. J Cardiovasc Risk. 1997;4(5-6):373-384.
33. Attebring M, Hartford M, Holm G, Wiklund O, Wahrborg P, Herlitz J. Risk indicators for recurrence among patients with coronary artery disease: Problems associated with their modification. Scand Cardiovasc J. 1998;32(1):9-16.
34. Haskell W, Alderman E, Fair J, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89(3):975-990.
35. Wilson T, Quest D, Wilson M, et al. A cardiovascular risk factor reduction clinic. Can J Cardiol. 1999;15(8):887-891.
36. Vicari RM, Wan GJ, Aura AM, Alexander CM, Markson LE, Teutsch SM. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. Arch Fam Med. 2000;9:898-905.
37. Khoury AT, Wan GJ, Niedermaier ON, et al. Improved cholesterol management in coronary heart disease patients enrolled in an HMO. J Healthc Qual. 2001;23(2):29-33.
38. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819-822.
39. McAlister FA, Lawson FME, Koon KT, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: Systematic review. BMJ. 2001;323:957-962.
40. LaBresh K. Get with the guidelines. Med Health R I. 2000;83(2):60-61.
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
42. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.